The United States Food and Drug Administration (FDA) recently convened an expert panel that has reignited a fierce debate over testosterone therapy. The committee argued for a significant policy shift, labeling testosterone replacement not just as a treatment for specific medical conditions, but as a “cornerstone of preventive health.” They viewed expanding access to the hormone as a multibillion-dollar opportunity to improve public health.
Currently, testosterone is approved in the U.S. only for individuals with clinically diagnosed low levels caused by specific medical issues, such as testicular damage or brain disorders. However, growing evidence and shifting cultural attitudes suggest that a broader population—including men and women with age-related declines—might benefit from the hormone. This proposal intensifies a long-standing conflict between clinicians who advocate for strict medical criteria and those who believe testosterone should be more readily available for general wellness.
The Core Controversy: Prevention vs. Lifestyle
The disagreement centers on who qualifies for treatment and why. The debate has fractured into three distinct viewpoints:
- The Conservative View: Many clinicians argue that most men with low testosterone, particularly young men without underlying medical causes, do not need medication. They assert that lifestyle changes, such as weight loss and improved diet, are sufficient to restore levels.
- The Symptomatic View: A middle ground suggests that men experiencing specific symptoms—such as fatigue, irritability, and low libido—should receive therapy, regardless of the root cause.
- The Preventive View: Enthusiastic proponents, including several FDA panel members, argue that all cisgender men should be tested. They contend that maintaining normal testosterone levels is crucial for preventing illness, even in asymptomatic individuals.
“You could make a very strong argument that having a normal testosterone level is important for health and prevention of illness,” said Abraham Morgentaler, a urologist at Harvard Medical School and participant in the FDA panel.
Despite these medical arguments, testosterone is increasingly marketed as a lifestyle enhancer. Influential figures like podcast host Joe Rogan have praised the hormone, and a surge of private clinics worldwide promise increased energy and muscle mass to people who may not have low testosterone at all. This cultural shift has blurred the line between medical necessity and cosmetic enhancement.
Safety Record: From Cancer Fears to Heart Health
The safety profile of testosterone has fluctuated dramatically since its synthesis in the 1930s. Initially hailed as a potent medicine, its reputation collapsed in the mid-20th century due to fears that it caused cancer. This fear stemmed from the work of urologist Charles Huggins, who discovered that prostate cancer relies on testosterone. His findings, which earned him a Nobel Prize, led to the belief that supplementing testosterone would fuel tumor growth.
However, subsequent research challenged this view. Morgentaler and other experts noted that early warnings were based on limited data, including observations of a single patient. Clinical experience showed that patients treated with testosterone did not develop cancer at higher rates. This helped revive interest in the therapy, though concerns remained.
Cardiovascular Risks Reevaluated
In 2013 and 2014, retrospective studies suggested an increased risk of heart attacks among men using testosterone, prompting the FDA to add a warning to product labels in 2015. This changed with the TRAVERSE trial, a large randomized study involving 5,200 men with low testosterone and high cardiovascular risk.
The study found no increased incidence of severe cardiovascular events (such as heart attacks or strokes) in men taking testosterone compared to those on a placebo. Based on these findings, the FDA removed the cardiovascular warning from testosterone products last year.
“This study only picked very sick people, the greatest-risk population, and nothing bad happened to them,” said Mohit Khera, a co-author of the TRAVERSE trial and urologist at Baylor College of Medicine.
The Danger of High Doses
While therapeutic doses (aimed at restoring levels to the normal range of 350–750 nanograms per decilitre) appear safe for the heart, high doses carry significant risks. Excessive testosterone can lead to:
* Cardiomyopathy: Thickening of the heart muscle, impairing blood pumping.
* Reproductive Issues: Infertility, shrunken testicles, and reduced sperm count.
* Neuropsychiatric Effects: Irritability, psychosis, and potentially increased aggression.
A Danish study tracking men using high-dose anabolic steroids (including medically approved testosterone) found their mortality rate was three times higher than non-users over seven years—a risk comparable to cocaine use. Approximately 30% of men on high doses become dependent, creating a cycle of addiction that floods clinics with patients seeking treatment for steroid misuse.
Who Actually Benefits?
While anecdotes from doctors like Morgentaler describe life-changing improvements in mood, patience, and libido, clinical trials tell a more nuanced story.
Sexual Function
The most consistent benefit is in sexual health. The TRAVERSE trial found that men taking testosterone reported a 25% greater increase in sexual activity compared to placebo. A meta-analysis by the Endocrine Society confirmed a “small but statistically significant” improvement in sexual satisfaction and libido. However, erectile function itself saw little to no improvement in the trial, though other reviews suggested minor benefits.
Physical Health
* Bone Density and Anaemia: Testosterone effectively treats anaemia and improves bone density.
* Muscle Mass: Smaller trials show increases in fat-free body mass and strength.
* Fractures: Surprisingly, men in the TRAVERSE trial had more fractures than the placebo group. Experts suggest this may be because inactive men became more active after treatment, leading to a higher risk of accidental injury—a potentially positive sign of increased mobility.
Limitations
Research found no statistically significant difference in energy, mood, or cognition between testosterone users and placebo groups. Additionally, adherence is a major issue: in the TRAVERSE trial, 61% of participants discontinued treatment, likely due to administration methods (injections, gels) or unmet expectations.
Women and Transgender Men: The Overlooked Patients
While the debate focuses on men, women and transgender individuals are largely excluded from the regulatory discussion.
Postmenopausal Women
For women, the only clear evidence of benefit is for low sexual desire causing distress. A systematic review of 36 trials showed testosterone outperformed placebo in this area, though the “placebo effect” remains powerful. Susan Davis, an endocrinologist at Monash University, notes that simply having a physician validate concerns often improves patient well-being.
- Safety: Therapeutic doses are generally safe, causing minor side effects like acne.
- Risks of High Doses: Higher doses can cause hair loss, weight gain, voice changes, and clitoral enlargement. Some women report agitation, aggression, or “road rage.”
- Regulatory Gap: Only four countries (Australia, New Zealand, South Africa, and the UK) have approved testosterone specifically for women. In the U.S., women often use male formulations off-label, posing potential safety risks.
Transgender Men
Testosterone is a standard part of gender-affirming care for trans men, yet the FDA panel did not address their specific needs. Davis argues that the FDA should approve female-specific doses to protect women from the risks associated with using male-formulated drugs.
Regulatory Hurdles and Future Directions
The regulatory landscape varies significantly by region:
* United States: Strictly limits approval to “classical hypogonadism” (low testosterone caused by genetic or physical disorders). However, the FDA recently invited applications for treating low libido in men with idiopathic (unknown cause) low testosterone.
* UK, Europe, Australia: Approve testosterone for men with lab-confirmed low levels and symptoms, regardless of the underlying cause.
The FDA panel’s recommendations could lead to further changes, such as removing testosterone’s classification as a controlled substance. Currently, it is classified as such due to its potential for abuse and historical doping scandals.
Conclusion
Testosterone therapy sits at the intersection of medical necessity and cultural desire. While recent data alleviates fears regarding cardiovascular health in therapeutic doses, the risks of high-dose misuse remain severe. The challenge for regulators and clinicians is to expand access for those who genuinely benefit—such as men with symptomatic hypogonadism and women with sexual dysfunction—while preventing the unchecked commercialization of a powerful hormone. The path forward requires balancing preventive health goals with rigorous safety standards to ensure that testosterone remains a medicine, not a commodity.
